These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15935595)

  • 1. Serum levels of cathepsin K decrease with age in both women and men.
    Kerschan-Schindl K; Hawa G; Kudlacek S; Woloszczuk W; Pietschmann P
    Exp Gerontol; 2005 Jun; 40(6):532-5. PubMed ID: 15935595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women.
    Prezelj J; Ostanek B; Logar DB; Marc J; Hawa G; Kocjan T
    Menopause; 2008; 15(2):369-73. PubMed ID: 17882010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status.
    Fahrleitner-Pammer A; Dobnig H; Piswanger-Soelkner C; Bonelli C; Dimai HP; Leb G; Obermayer-Pietsch B
    Wien Klin Wochenschr; 2003 May; 115(9):291-7. PubMed ID: 12793029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
    Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlates of osteoprotegerin levels in women and men.
    Khosla S; Arrighi HM; Melton LJ; Atkinson EJ; O'Fallon WM; Dunstan C; Riggs BL
    Osteoporos Int; 2002 May; 13(5):394-9. PubMed ID: 12086350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status.
    Szulc P; Hofbauer LC; Heufelder AE; Roth S; Delmas PD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3162-5. PubMed ID: 11443182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum IGFBP-2 is predictive of increased bone turnover in aging men and women.
    Amin S; Riggs BL; Melton LJ; Achenbach SJ; Atkinson EJ; Khosla S
    J Bone Miner Res; 2007 Jun; 22(6):799-807. PubMed ID: 17352648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
    Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
    J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
    Indridason OS; Franzson L; Sigurdsson G
    Osteoporos Int; 2005 Apr; 16(4):417-23. PubMed ID: 15776220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
    Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High cathepsin K levels in men with differentiated thyroid cancer on suppressive L-thyroxine therapy.
    Mikosch P; Kerschan-Schindl K; Woloszczuk W; Stettner H; Kudlacek S; Kresnik E; Gallowitsch HJ; Lind P; Pietschmann P
    Thyroid; 2008 Jan; 18(1):27-33. PubMed ID: 18302515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease.
    Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ
    Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.
    Leder BZ; Finkelstein JS
    Osteoporos Int; 2005 Dec; 16(12):1487-94. PubMed ID: 15856361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial.
    Hampson G; Martin FC; Moffat K; Vaja S; Sankaralingam S; Cheung J; Blake GM; Fogelman I
    Osteoporos Int; 2003 Sep; 14(9):750-6. PubMed ID: 12904840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.